Trials / Completed
CompletedNCT00337662
Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia
Predicting Response to Risperidone Treatment Through Identification of Early-onset of Antipsychotic Drug Action in Schizophrenia.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 628 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The current study has been designed to address the significance of early onset of response prospectively in patients treated with an atypical antipsychotic.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | olanzapine | 10-20 milligrams (mg), oral, daily, 10 weeks. |
| DRUG | risperidone | 2-6 mg, oral, daily, for 10 weeks. |
| DRUG | risperidone | 2-6 mg, oral, daily, 10 weeks |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2006-06-16
- Last updated
- 2010-02-17
- Results posted
- 2009-08-04
Locations
34 sites across 3 countries: United States, Argentina, Russia
Source: ClinicalTrials.gov record NCT00337662. Inclusion in this directory is not an endorsement.